Telomir Pharmaceuticals, Inc. Common Stock
TELO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $2 | $1 | $0 |
| G&A Expenses | $10 | $1 | $0 | $0 |
| SG&A Expenses | $10 | $1 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2 | $0 | $0 |
| Operating Expenses | $12 | $4 | $1 | $0 |
| Operating Income | -$12 | -$4 | -$1 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$4 | -$9 | $0 | $0 |
| Pre-Tax Income | -$17 | -$13 | -$1 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17 | -$13 | -$1 | -$0 |
| % Margin | – | – | – | – |
| EPS | -0.56 | -0.44 | -0.029 | -0.005 |
| % Growth | -27.3% | -1,427.8% | -512.8% | – |
| EPS Diluted | -0.56 | -0.44 | -0.029 | -0.005 |
| Weighted Avg Shares Out | 30 | 30 | 30 | 30 |
| Weighted Avg Shares Out Dil | 30 | 30 | 30 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$4 | $2 | $0 | $0 |
| Depreciation & Amortization | $12 | $0 | $1 | $0 |
| EBITDA | $0 | -$11 | $0 | $0 |
| % Margin | – | – | – | – |